Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
0.741
-0.039 (-5.03%)
At close: Mar 9, 2026, 4:00 PM EDT
0.755
+0.014 (1.89%)
After-hours: Mar 9, 2026, 7:46 PM EDT
Scinai Immunotherapeutics Employees
Scinai Immunotherapeutics had 31 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
31
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$37,000
Profits / Employee
$11,194
Market Cap
2.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Calidi Biotherapeutics | 28 |
| Azitra | 12 |
| Dermata Therapeutics | 8 |
| Artelo Biosciences | 7 |
| Enveric Biosciences | 6 |
| 60 Degrees Pharmaceuticals | 3 |
| PMGC Holdings | 3 |
SCNI News
- 7 days ago - Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - PRNewsWire
- 12 days ago - Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - PRNewsWire
- 20 days ago - Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - PRNewsWire
- 2 months ago - Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - PRNewsWire
- 3 months ago - Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - PRNewsWire
- 5 months ago - Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities - PRNewsWire
- 6 months ago - Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - PRNewsWire
- 7 months ago - Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - PRNewsWire